clinical rationale for cabozantinib in hcc
Published 5 years ago • 243 plays • Length 6:00Download video MP4
Download video MP3
Similar videos
-
6:30
the rationale for using cabozantinib
-
1:18
dr. abou-alfa on the fda approval of cabozantinib in hcc
-
0:54
dr. singal on the fda approval of cabozantinib in hcc
-
2:45
sequencing with cabozantinib in advanced hcc
-
0:51
dr. pal on the rationale for adding cabozantinib to atezolizumab in prostate cancer
-
5:56
the rationale for cabozantinib in advanced rcc
-
1:43
clinical rationale for tki choice in mrcc
-
6:39
emerging second-line therapies in hcc
-
3:16
cabosun: upfront use of cabozantinib for mrcc
-
4:58
emerging c-met inhibitors in hcc
-
2:33
celestial trial: second-line cabozantinib’s value in hcc
-
2:47
cabozantinib in mrcc
-
3:15
advances in systemic therapy for hcc
-
4:11
second-line treatment for hepatocellular carcinoma
-
3:56
comparative efficacy of cabozantinib and regorafenib for advanced hepatocellular carcinoma
-
1:24
ahmed kaseb, md, on combining cabozantinib with checkpoint inhibitors for treatment of hcc
-
1:36
cabozantinib in patients with hcc refractory to checkpoint inhibitors
-
6:54
diagnostic workup for hcc
-
5:40
vegf-targeted therapy in hcc: ramucirumab